Combining Topical Psoriasis Treatment to Enhance Systemic and Phototherapy: A Review of the Literature
December 2017 | Volume 16 | Issue 12 | Original Article | 1209 | Copyright © 2017
Jerry Bagel MD,a and Linda Stein Gold MDb
aPsoriasis Treatment Center of Central New Jersey, East Windsor, NJ bHenry Ford Health System, Detroit, MI
Psoriasis is a chronic inflammatory skin disease that affects millions of people in the United States as well as worldwide. While there is currently no cure for psoriasis, many treatment options are available. Topical therapies are the mainstay for the majority of patients who have limited or mild psoriasis. Among these medications, topical vitamin D analogs (eg, calcipotriene) and corticosteroids (eg, betamethasone), and these drugs in combination, are the most widely prescribed psoriasis drugs and are the cornerstone of topical therapies. For patients with more severe disease, phototherapy, conventional systemic agents, and biologics are often indicated. Currently, the goal of treatment is to control the clinical symptoms of the skin, reduce systemic disease potential, and improve the patient’s quality of life. Despite the availability of various therapeutic options for psoriasis, many patients go untreated, and even among those who are treated, many do not achieve complete resolution of the disease. The new consensus is to treat to a target of 1% or less of body surface area involvement. Innovative treatment strategies are needed to meet this goal and patients’ desire to achieve clear skin. Combination therapies are widely used by physicians, and adjunctive topical therapies used with other antipsoriatic regimens have been demonstrated to provide many clinical benefts. This article reviews the most recently published clinical evidence of adjunctive use of topical agents with biologics, conventional systemic agents, and phototherapy, to better establish the role of topical agents in combination therapy for the treatment of psoriasis.
J Drugs Dermatol. 2017;16(12):1209-1222.
Purchase Original Article
Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.
Download the original manuscript as it was published in the JDD.
Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.
To get access to JDD's full-text articles and archives, upgrade here.
Save an unformatted copy of this article for on-screen viewing.
Print the full-text of article as it appears on the JDD site.→ proceed | ↑ close
Psoriasis is a chronic inflammatory skin disease that is characterized by disfiguring, scaling, and erythematous plaques that can be painful or severely pruritic.1 In the United States, an estimated 7.4 million adults are living with psoriasis.2 The severity of psoriasis is defined by both the extent of body surface area (BSA) affected and whether the lesions involve crucial body areas, such as the hands, feet, face, or genitals; however, there is no clear unifying definition of mild, moderate, or severe psoriasis.3 The American Academy of Dermatology has defined mild, moderate, and severe psoriasis as <5%, ≥5% to <10%, and ≥10% BSA involvement, respectively. In clinical trials, ≥10% BSA involvement is required for classification as moderate-to-severe psoriasis.3 Most patients seen in clinical practice have mild-to-moderate psoriasis (~80%), whereas moderate-to-severe disease affects about 20% of patients.3 Psoriasis is associated with significant morbidity and comorbidity, such as autoimmune diseases, cardiovascular disease, and metabolic syndrome, which, especially in severe disease, can increase mortality risk.1 Psoriasis can significantly affect the physical, social, and psychological well-being of the patient, leading to a deterioration in quality of life comparable to that noted with other severe chronic diseases, such as cancer.4Although the pathogenesis of psoriasis has not been fully elucidated, both genetic and environmental factors are now known to contribute to the development of the disease. Increased understanding of the mechanism of psoriasis has led to the development of a variety of new antipsoriatic therapies that target key steps in its pathogenesis.
Psoriasis Treatment Options and Goals
There is no cure for psoriasis at this time.5 The treatment goal remains to control clinical symptoms of the skin, reduce systemic disease potential, and to improve the patient’s quality of life.5 Topical medications are still the mainstay of therapy for the majority of patients when the disease is limited or mild.1,3 Among these medications, topical vitamin D analogs (eg, calcipotriene) and corticosteroids (eg, betamethasone), and these drugs in combination, are the most widely prescribed psoriasis drugs and are the cornerstone of topical therapies.6,7 Extensive treatment options, involving biologics, traditional systemic therapies, or phototherapy, are often reserved for patients with moderate-to-severe disease.1,3 Biologic agents have taken forefront in the treatment of moderate-to-severe psoriasis, in view of their favorable risk/benefit ratio; nevertheless,